Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2022-06-22 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - AVR 9 pages 33.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options exercised or convertible securities converted. It includes specifics such as the number of securities, issue dates, issue prices, and classifications of securities (quoted and unquoted). There is no indication of financial statements, management discussion, earnings data, or regulatory certifications. The document is an announcement related to the quotation of securities on the ASX (Australian Securities Exchange), which aligns with updates on capital structure changes or financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (9168 characters) is sufficient to contain substantive information, not just a brief announcement or report publication notice.
2022-06-22 English
DurAVR First In Human Patient 6 Month Study Follow Up 2 pages 173.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 June 2022 reporting clinical follow-up results of a medical device (DurAVR™ heart valve) at 6 months. It provides updates on patient outcomes and device performance but does not contain financial statements, regulatory certifications, or detailed financial data. The document is relatively short (3630 characters) and serves as a progress update rather than a formal financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of clinical trial follow-up results, which is best categorized under general regulatory announcements or miscellaneous filings. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-06-20 English
Notification regarding unquoted securities - AVR 11 pages 38.8KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notification about the issue of unquoted equity securities, specifically unlisted options issued to directors as approved at the AGM. It includes specifics such as exercise prices, expiry dates, number of securities issued, and references to shareholder approval at the AGM held on 25 May 2022. The document is an official announcement of securities issuance, focusing on capital structure changes and director remuneration via options. It is not a full financial report, audit, or earnings release, nor is it a voting result or management change announcement. The content aligns with updates on company fundraising or capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of securities issuance.
2022-06-16 English
Change of Director's Interest Notice x4 9 pages 358.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including acquisitions and disposals of shares and options. The content is focused on reporting personal share transactions by directors, including dates, number of securities before and after changes, and nature of changes. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure of insider trades by directors, which matches the definition of 'Director's Dealing' filings.
2022-06-16 English
Application for quotation of securities - AVR 12 pages 40.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, prices, and classifications of securities. There is no indication of financial statements, management discussion, earnings data, or regulatory certifications. The document is an announcement related to the quotation of securities on the ASX (Australian Securities Exchange), which aligns with updates on capital structure changes or financing activities. Therefore, this document fits best under the category 'Capital/Financing Update' (CAP). The document length is substantial (over 13,000 characters), indicating it is not a brief announcement or a simple report publication notice, but a detailed application for quotation of securities.
2022-06-16 English
Cleansing Notice 2 pages 167.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 June 2022 regarding the issuance of 1,500 new fully paid ordinary shares due to the conversion of unlisted options. It references compliance with the Corporations Act 2001 and provides a cleansing notice under section 708A(5)(e). The content focuses on a capital raising event through share issuance and legal compliance notices related to that issuance. There are no financial statements, management discussion, or detailed financial data. The document is short (2991 characters) and is an announcement of a capital/financing activity rather than a full report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP).
2022-06-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.